IMMIX WKN: A3C9EJ ISIN: US45258H1068 Kürzel: IMMX Forum: Aktien User: DeRitter

Immix Biopharma (NASDAQ:IMMX) announced the closing of an upsized underwritten registered offering on Dec 9, 2025 consisting of 19,117,646 shares of common stock at $5.10 per share and 490,196 pre-funded warrants at $5.09 each. Net proceeds to the company after underwriting discounts, commissions and offering expenses were approximately $93.7 million. The financing included leading U.S. biotechnology institutional investors and mutual funds, with Morgan Stanley as sole book‑running manager and Citizens Capital Markets and Mizuho as co‑managers. The securities were offered under a shelf registration statement (Form S-3, File No. 333-269100) declared effective Jan 11, 2023; a prospectus supplement was filed with the SEC and is available on the SEC website.

Sehr schön 😊

Immix Biopharma subsidiary Nexcella has received FDA Orphan Drug Designation for Revlucabtagene Autoleucel (NXC-201) for treatment of amyloid light chain amyloidosis.

Sehr schön, kann weiter so steigen☺️

😮

🫣

👀

🙋🏻‍♀️

🤔

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

🎈

🎈

Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

🎈